Meeting
2023 ASCO Quality Care Symposium
Heterogeneity in costs of standard-of-care drug regimens within high volume Enhancing Oncology Model disease groups: Implications for performance risk outside of a provider’s control.
Authors
Katherine Baker
Vanderbilt-Ingram Cancer Center, Nashville, TN
Katherine Baker, Garrett Young, Larry Edward Bilbrey, Samyukta Mullangi, Aaron J. Lyss, Natalie R. Dickson, Leah Owens, Stephen Matthew Schleicher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Value-Based Models of Care
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 70)
DOI
10.1200/OP.2023.19.11_suppl.70
Abstract #
70
Poster Bd #
C23
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.
First Author: Soong June Bae
Poster
2016 ASCO Annual Meeting
Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.
First Author: Jeremy Meyer Force
Poster
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
First Author: Teng Zhu
Poster
2013 ASCO Annual Meeting
NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.
First Author: Louis Fehrenbacher